CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI) Files An 8-K Other EventsITEM 8.01.OTHER EVENTS.
On September 28, 2017, the Company issued a press release entitled "Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test". A copy of the press release is included herewith as Exhibit99.1 and incorporated herein by reference.
ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS
Exhibits.
|
99.1 |
Press Release entitled "Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test" dated September 28, 2017. |
CHEMBIO DIAGNOSTICS, INC. ExhibitEX-99 2 ex99_1.htm EXHIBIT 99.1 FOR PR Chembio Diagnostics Receives FDA Emergency Use Authorization for the First Rapid Zika IgM Test MEDFORD,…To view the full exhibit click here
About CHEMBIO DIAGNOSTICS, INC. (NASDAQ:CEMI)
Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company’s product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.
